Theralase Technologies Inc. V.TLT

RE:RE:Theralase Covid Vaccine with 99.99% Kill Rate!!!

[CancerSlayer]

CancerSlayer wrote:

Infinity wrote: I understand that animal test studies are in progress with NML using PHAC guidelines.  Can anyone of the experts on this board through some light on the 99.99% kill rate?  How would this translate in terms of efficacy and safety (Human Trial stage).

Quote from Dr. Mandel: "Theralase® is pleased to be able to report today that PHAC has demonstrated that light-activated TLD-1433, was effective in rapidly inactivating the SARS-CoV-2 virus by up to 99.99%, compared to control in an in vitro study.  Further research is required to confirm these findings."

 

 

 

 

Would like to see that in vitro 99.99% kill rate reproduced in vivo.  While such a high kill rate bodes well for further vaccine development, the vaccine space is crowded with multiple effective vaccines currently in use (particularly the mRNA-based vaccines).  I'd like to see similar attention/funding directed towards the in vivo investigation of TLD 1433 as an anti-viral "treatment" option for both mild & more severe Covid-19 cases.  Finding simpler non-intravenous treatment options in the less competitive outpatient/non-hospitallized space should be similarly prioritized imo.  Currently, Pfizer's Paxlovid is the only simple treatment option (oral) that has shown good efficacy in outpatients.  More options in this space are certainly needed.  Good luck...

 

Table B. Dosing Regimens for the Drugs Recommended for High-Risk, Nonhospitalized Adults With Mild to Moderate COVID-19, Listed in Order of Preference Based on Efficacy and Convenience of Use 

Drug Name	Dosing Regimen	Time From Symptom Onseta
Ritonavir-Boosted Nirmatrelvir (Paxlovid)	eGFR ≥60 mL/min: Nirmatrelvir 300 mg with RTV 100 mg PO twice daily for 5 days eGFR ≥30 to <60 mL/min: Nirmatrelvir 150 mg with RTV 100 mg PO twice daily for 5 days eGFR <30 mL/min: Not recommended Severe Hepatic Impairment (Child-Pugh Class C):  Not recommended	≤5 days
Remdesivir	RDV 200 mg IV on Day 1, followed by RDV 100 mg IV once daily on Days 2 and 3.b,c Each infusion should be administered over 30–120 minutes. Patients should be observed for ≥1 hour after infusion as clinically appropriate.	≤7 days
Bebtelovimab	BEB 175 mg as a single IV injection, administered over ≥30 seconds. Patients should be observed for ≥1 hour after injection.	≤7 days
Molnupiravir	Molnupiravir 800 mg PO twice daily for 5 days	≤5 days
a Per EUA criteria or clinical trial entry criteria. b An eGFR <30 mL/min at screening or <90 days before screening was considered an exclusion criterion in the outpatient RDV study PINETREE, but only if a participant’s weight was <48 kg. See the Remdesivir section for a discussion of RDV use in patients with renal impairment. c If RDV is administered to patients who have a new or increasing need for supplemental oxygen but who are discharged from the ED because hospital resources are limited and inpatient admission is not possible, the total duration of therapy is ≤5 days.   Key: BEB = bebtelovimab; ED = emergency department; eGFR = estimated glomerular filtration rate; EUA = Emergency Use Authorization; IV = intravenous; PO = orally; RDV = remdesivir; RTV = ritonavir

 

*PO = given orally